Rheumatoid Arthritis News

Patients across health care specialties have in recent years come to expect some form of individually tailored care — or precision medicine — as part of their disease management.

The FDA has granted 510(k) clearance to Werfen for its Aptiva Connective Tissue Disease Essential reagent to assist in the diagnosis of patients with autoimmune diseases, according to a manufacturer press release.

For patients with diseases such as lupus or rheumatoid arthritis who take low-dose drugs at lower frequencies, the relief afforded by over-the-counter drugs such as ibuprofen and naproxen can be a boon.

In patients with rheumatoid arthritis, NSAIDs and opioids demonstrate similar risks for major adverse cardiovascular events, while opioids exhibit higher rates of all-cause mortality and venous thromboembolism, according to data.

Patients receiving tofacitinib for rheumatoid arthritis with higher paraoxonase activity over time demonstrate a lower risk for major adverse cardiovascular events and malignancy, according to data published in the Journal of Rheumatology.

The FDA has approved Abrilada as the second interchangeable biosimilar to adalimumab, according to a press release from Pfizer.

Adalimumab-adbm injection is now available at a low wholesale acquisition cost, Boehringer Ingelheim announced in a company press release.

Patients with rheumatoid arthritis who receive abatacept or certolizumab pegol achieve clinical remission at higher rates than those receiving active conventional therapy, according to data published in Annals of the Rheumatic Diseases.

Although the current net price of adalimumab biosimilar Amjevita is lower for commercial health plans than that of the originator, it is nonetheless “more than double” what Humira cost at launch in 2003, according to a research letter.

The FDA has approved Tofidence as the first tocilizumab biosimilar in the United States for the treatment of rheumatoid arthritis and other conditions, according to a statement from the manufacturer.